Association between anti-tuberculosis drug resistance-conferring mutations and treatment outcomes in Myanmar
Infect Dis (Lond)
.
2018 May;50(5):388-390.
doi: 10.1080/23744235.2017.1404632.
Epub 2017 Dec 1.
Authors
Htin Lin Aung
1
,
Thanda Tun
2
,
Wint Wint Nyunt
3
,
Yang Fong
4
,
John A Crump
5
,
Kyi Kyi Thinn
6
,
Si Thu Aung
7
,
Gregory M Cook
1
Affiliations
1
a Department of Microbiology and Immunology, School of Biomedical Sciences , University of Otago , Dunedin , New Zealand.
2
b National Health Laboratory , Ministry of Health and Sports , Yangon , Myanmar.
3
c National Tuberculosis Reference Laboratory , Ministry of Health and Sports , Yangon , Myanmar.
4
d Massey Genome Service , Institute of Fundamental Science, Massey University , Palmerston North , New Zealand.
5
e Centre for International Health, Dunedin School of Medicine , University of Otago , Dunedin , New Zealand.
6
f Department of Microbiology , University of Medicine 1 , Yangon , Myanmar.
7
g National Tuberculosis Programme, Ministry of Health and Sports , Naypyitaw , Myanmar.
PMID:
29192532
DOI:
10.1080/23744235.2017.1404632
No abstract available
Publication types
Letter
Comment
MeSH terms
Antitubercular Agents*
Humans
Mutation
Myanmar
Mycobacterium tuberculosis
Treatment Outcome
Tuberculosis*
Substances
Antitubercular Agents